Updated clinical practice guidelines for the prevention and treatment of mucositis (Q36712445)

15 August 2017

Updated clinical practice guidelines for the prevention and treatment of mucositis (English)

1 reference

15 August 2017

Judith E Raber-Durlacher

6

object named as

Judith E Raber-Durlacher

1 reference

15 August 2017

Dorothy M Keefe

1

1 reference

15 August 2017

Mark M Schubert

2

1 reference

15 August 2017

Linda S Elting

3

1 reference

15 August 2017

Stephen T Sonis

4

1 reference

15 August 2017

Joel B Epstein

5

1 reference

15 August 2017

Cesar A Migliorati

7

1 reference

15 August 2017

Deborah B McGuire

8

1 reference

15 August 2017

Ronald D Hutchins

9

1 reference

15 August 2017

Douglas E Peterson

10

1 reference

15 August 2017

Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology

11

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

15 August 2017

1 reference

15 August 2017

109

1 reference

15 August 2017

820-831

1 reference

15 August 2017

5

1 reference

Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients

15 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Rating the quality of evidence for clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Mucositis guidelines: what have they achieved, and where to from here?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Alimentary tract mucositis in cancer patients: impact of terminology and assessment on research and clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

New thoughts on the pathobiology of regimen-related mucosal injury.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

The role of basic oral care and good clinical practice principles in the management of oral mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Promulgation of guidelines for mucositis management: educating health care professionals and patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Anti-inflammatory agents in the management of alimentary mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Amifostine in the management of radiation-induced and chemo-induced mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Alimentary mucositis: putting the guidelines into practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Occurrence of symptom clusters

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Assessment and measurement of oral mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Symptom clusters: the new frontier in symptom management research

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Gastrointestinal mucositis: a new biological model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Barriers and strategies in implementation of oral care standards for cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucosi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Intrarectal application of amifostine for the prevention of radiation-induced rectal injury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

The pathobiology of mucositis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Palifermin for oral mucositis after intensive therapy for hematologic cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Prevention of high-dose melphalan-induced mucositis by cryotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, ran

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22484

7 January 2021

Identifiers

DOI

10.1002/CNCR.22484

1 reference

15 August 2017

1 reference